The earliest UK private access via online pharmacies is likely in 2027 or 2028, with NHS access following a NICE appraisal
It's currently undergoing Phase 3 clinical trials, so it's not yet fully FDA-approved for commercial prescription or public use
[DOI] [PubMed] [Google Scholar] 33.Solomon S.D., McMurray J.J.V., Claggett B., De Boer R.A., DeMets D., Hernandez A.F., Inzucchi S.E., Kosiborod M.N., Lam C.S.P., Martinez F., et al
Fair Use This content is available for non-commercial reuse with proper attribution
In a previous piece covering semaglutide and other GLP-1 medication, we discussed some of the ways that employers are adapting in order to offer these drug treatments to employees without exposing the health plan to out-of-control costs, including implementing lifetime caps, minimum BMI caps, and limiting access to cheaper GLP-1 options: Lifetime Cap : Some employers are limiting their exposure to excessive GLP-1 weight loss expenses by setting a lifetime cap on the amount of funds available to covered employees
